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CD44. If, as this study suggests, the inter-
action of CD44 with the extracellular envi-
ronment does not play a role in effector
T cell migration, it appears that during
effector differentiation, T cells develop
a dependency on CD44 to polarize. This
conclusion could be tested by investi-
gating the migration of effector T cells in
lymph nodes and examining whether the
tissue environment contributes to the
differential behavior of naive and effector
cells.
Beyond providing new insights into the
biology of CD44, this study also makes
an important contribution by highlighting
the relevance of events that take place in
peripheral tissues subsequent to recruit-
ment from the blood in determining the
outcome of T cell responses. It is conceiv-
able that apart from the ability to migrate
properly, T cells need to execute many
other cellular functions that are subjected
to extrinsic regulation in order to carry out
their tasks.
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Rare HIV-1-infected individuals are able to control viral replication without antiretroviral therapy. In this issue
of Immunity, Migueles et al. (2008) show that HIV-1-specific CD8+ T cells from these individuals effectively
suppress viral replication by granzyme B-mediated killing of target cells.HIV-1 normally replicates vigorously in
untreated patients leading to global
immune activation, progressive CD4+
T cell depletion, and eventually frank
AIDS. This progressive course is not
seen in a select group of untreated
patients who suppress viral replication to
levels below the limit of detection of
commercial assays. These individuals,
who represent less than 0.5% of all HIV-
1-infected patients, have been called elite
controllers, elite suppressors, or HIV
controllers (Deeks and Walker, 2007). In
this issue of Immunity, Migueles et al.
(2008) refer to them simply as long-term
nonprogressors, but this term has tradi-
tionally been used to describe patients
who maintain relatively high CD4+ counts
for prolonged periods of time regardless
of the level of viral replication. The termHIV controllers (HCs) will therefore be
used in this preview. Understanding the
mechanisms responsible for the remark-
able control of viral replication in these
patients will obviously have major implica-
tions for the design of effective HIV-1
vaccines.
In a recent study, replication-compe-
tent HIV-1 was isolated from some HCs,
and detailed genotypic and phenotypic
analyses strongly suggested that these
isolates were fully virulent (Blankson
et al., 2007). Furthermore, a case of trans-
mission of HIV-1 from a patient who
developed AIDS to a subject who has
been an HC for 10 years has recently
been reported (Bailey et al., 2008). This
provides strong evidence that unique
host factors, and not infection with atten-
uated HIV-1 isolates, can explain the eliteImmunity 29, Dcontrol of HIV-1 replication in at least
some of these individuals. The search is
on to determine exactly what these
protective host factors are. The most
consistent finding in studies of HCs is
that certain class I HLA alleles such as
HLA-B*57 and HLA-B*27 are overrepre-
sented in HCs compared to both the
general population and cohorts of HIV-
1-infected patients with progressive
disease (Deeks and Walker, 2007).
Furthermore, whole-genome association
scan analysis of HIV-1-infected individ-
uals has shown that the factors most
strongly associated with protection
against disease are either HLA alleles
(Fellay et al., 2007; Catano et al., 2008)
or a single-nucleotide polymorphism that
is in linkage disequilibrium with HLA-
B*5701 (Fellay et al., 2007). Takenecember 19, 2008 ª2008 Elsevier Inc. 845
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Previewstogether, these results suggest that
certain class I HLA molecules play a major
role in HC status. It should be noted,
however, that some HCs have none of
the protective alleles, and some patients
who do have these alleles develop
progressive HIV-1 disease. Thus, al-
though these host alleles are clearly
important, they are neither necessary nor
sufficient for elite suppression of viral
replication.
One way that class I HLA molecules
may directly contribute to the outcome
of HIV-1 infection is by the presentation
of processed peptide antigens to CD8+
T cells. It has been known for many years
that these effector cells are important for
the initial partial control of HIV-1 replica-
tion after the peak viremia in primary
infection. However, there is no correlation
between the frequency of HIV-1-specific
CD8+ T cells and the degree of viremia
present in the chronic phase of infection.
Although studies of HIV-1-specific CD8+
T cells have relied mostly upon assays
that measured IFN-g secretion in
response to stimulation with processed
peptides, recently developed assays
have shown important qualitative differ-
ences in HIV-1-specific CD8+ T cell func-
tion in HCs versus chronic progressors
(CPs). For example, there is a dramatic
difference in the proliferative capacity of
CD8+ T cells specific for an immunodomi-
nant epitope in the HIV-1 gag protein
between HLA-B*57-positive HCs and
CPs (Migueles et al., 2002). This
enhanced proliferation was associated
with expression of the lytic granule protein
perforin, which plays a central role in the
mechanism by which CD8+ T cells kill vir-
ally infected target cells. In addition, CD8+
T cells from HCs are more likely to secrete
multiple cytokines in response to stimula-
tion with HIV-1 peptides whereas those
from CPs generally secrete only IFN-g or
MIP1b (Betts et al., 2006). A more recent
study show that unstimulated CD8+
T cells from HCs are able to dramatically
suppress HIV-1 replication in autologous
CD4+ T cells, whereas those from CPs
could not (Saez-Cirion et al., 2007).
These studies all underscore the point
that the differences between the CD8+
T cell responses of HCs and CPs are qual-
itative rather than quantitative in nature,
but it is not clear how these differences
translate to the effective control of viral
replication in HCs. Proliferation would be
expected to increase the frequency of
effector cells, but, as noted above, more
HIV-1-specific CD8+ T cells does not
necessarily mean better control of
viremia. Similarly, cytokines such as IFN-
g, TNF-a, and IL-2 have not been shown
to inhibit HIV-1 replication directly. Other
studies have shown that the ability of un-
stimulated CD8+ T cells to inhibit viral
replication is contact dependent and
thus not due to the secretion of soluble
factors (Saez-Cirion et al., 2007).
In this issue, Migueles et al. (2008)
perform a series of elegant experiments
that further our understanding of the
mechanisms involved in the control of
viral replication. The investigators looked
at the cytotoxic potential of CD8+ T cells
that had been freshly isolated from HCs
and CPs versus cells from these subjects
that had been stimulated in vitro with
HIV-1 antigens for 6 days. They found
a marked increase in killing of autologous
CD4+ target cells that were pulsed with
immunodominant HIV-1 peptides by stim-
ulated CD8+ T cells from HCs but not CPs
(Figure 1). HIV-1-specific CD8+ T cells
from HCs proliferated to a greater degree
than those of CPs in response to in vitro
stimulation with HIV-1 antigen, resulting
in a much higher frequency of effector
cells in HCs. Although there was no
difference in the degranulation capacity
of stimulated HIV-1-specific CD8+ T cells
from HCs versus CPs, a greater per-
centage of cells from HCs contained per-
forin and granzyme B.
A recently developed flow cytometric
assay that measures granzyme B-medi-
ated substrate cleavage in target cells
was used to further investigate the
observed cytoxicity. This assay allowed
the investigators to determine the degree
of exocytosis of functional granzyme B as
opposed to the amount of total granzyme
B present in the effector cells. It is more
quantitative than the traditional chromium
release assays because it allows the inde-
pendent visualization of individual target
cells and effector cells (by tetramer stain-
ing). Stimulated HIV-1-specific CD8+
T cells from HCs generated dramatically
higher amounts of granzyme B exocytosis
than did cells from CPs. This finding was
confirmed by measuring the frequency
of HIV-1-infected target cells that re-
mained after coculture with stimulated
effector cells. The enhanced cytotoxicity
was seen even at very low effector to
target cell ratios in HCs whereas it was
minimal at even high effector to target
ratios in CPs. Thus the enhanced cyto-
toxicity was not simply the result of
a greater number of HIV-1-specific effec-
tors in HCs as a result of enhanced
proliferation that occurred during the
Ag-driven activation and
expansion of HIV-specific CTL
Progressor HIV controller
Figure 1. Response of HIV-1-Specific CD8+ T Cells in Progressors versus HIV Controllers
After stimulation with HIV-1 antigen, CD8+ T cells (orange) from both groups of patients secrete substantial
amounts of IFN-g (red dots), but efficient proliferation and clonal expansion is seen only in HIV controllers.
In addition to proliferation, HIV-1-specific CD8+ T cells from HIV controllers contain more granzyme B and
perforin than do those from progressors (depicted as granules within CD8+ T cells). This leads to dramatic
killing of HIV-1-infected target CD4+ T cells (blue) before the virus (black dots) can complete its life cycle.
In progressors, lower amounts of granzyme B and perforin may be the cause of inefficient killing of
HIV-1-infected CD4+ T cells.
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Previewsstimulation process. It was also not due to
activation-induced cell death of effector
cells from CPs, as indicated by the fact
that these cells could still secrete large
amounts of IFN-g. The granzyme B-medi-
ated killing occurred within one hour,
which is important because productively
infected CD4+ T cells have a half-life of
less than 1 day. It follows that the effector
cells could kill infected targets before
HIV-1 could complete its life cycle and
release virions that could perpetuate the
infection.
Prior studies have shown that HIV-1-
specific CD8+ T cells from CPs have a
block in proliferation and thus could be
considered partially anergic (Migueles
et al., 2002). This block is not a direct
consequence of HIV-1 viremia alone
because it is not reversed by treatment
with a potent cocktail of antiretroviral
drugs known as highly active antiretroviral
therapy (HAART). Interestingly, this study
shows that the block in proliferation of
HIV-1-specific CD8+ T cells can be over-
come by treatment with phorbol-12-myr-
istate 13-acetate (PMA) and ionomycin.
After a period of rest, restimulation with
HIV-1 antigens results in effectors from
CPs that are as good at granzyme
B-mediated killing of target cells as
effector cells from HCs.
The data from this study define at least
one mechanism responsible for CD8+
T cell-mediated suppression of HIV-1
replication, but there are many more
questions that need to be addressed.
Why do some patients become HCs andothers CPs even when they share the
same protective HLA alleles? Is this just
a consequence of differences in their
ability to develop effective killer cells? Is
the impressive granzyme B-mediated
killing seen in HCs limited to just HIV-1-
specific CD8+ T cells or is it a more
general phenomenon? If HIV-1 viremia is
not the cause of the partial anergy seen
in CPs, what is? Studies have shown
that HIV-specific CD8+ T cells are clearly
exerting selective pressure on HIV-1 in
HCs (Bailey et al., 2006). Why then is this
granzyme B-mediated killing not seen in
freshly isolated cells from HCs when
these cells are presumably responsible
for the control of HIV-1-infected cells
in vivo? Why does proliferation appear to
be a requirement for generating effective
killer cells that are capable of releasing
granzyme B? It will take a while before
all this is sorted out, but this study by
Migueles et al. (2008) provides reason
for optimism. They have described an
important CD8+ T cell function that corre-
lates with immune protection. It will be
important to test the ability of T cell-
directed candidate vaccines to induce
granzyme B-mediated killing of target
cells. The finding that the stimulation
of CPs cells with agonists that induce
proliferation results in effective HIV-1-
specific killers is an important proof of
concept study that suggests that the
partial anergy of HIV-1-specific CD8+
T cells is reversible. Thus, therapeutic
vaccination of CPs might eventually be
a feasible goal.Immunity 29,REFERENCES
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